Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm
Mandate

Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm

June 20, 2024 Intellectual Property Capital Markets and Public M&A Corporate Tax Employment and Benefits IT, Telecommunications and Outsourcing Banking and Finance

Vinge advises Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) in connection with an offering of new ordinary shares and listing on Nasdaq Stockholm. The first day of trading is 20 June 2024.

The offering will provide Cinclus Pharma with proceeds of approximately SEK 787 million before deduction of issue costs and provided that the over-allotment option is fully exercised. In connection with the offering, Cinclus Pharma also carries out a set-off issue at the offering price to convert outstanding bridge loans. 

Cinclus Pharma is a clinical-stage pharmaceutical company focused on the development of the drug candidate linaprazan glurate, a proprietary “prodrug” of the molecule linaprazan. Linaprazan glurate represents a new and innovative mode of action for the treatment of erosive GERD.

Vinge's team mainly consists of Dain Hård Nevonen,Amanda Knutsson, Anna Svensson,Michaela Ådén and Filip Magnusson (Capital Markets and Public M&A), Stojan Arnestål (IP/Life science), Maria Schultzberg (Corporate taxation), Mathilda Persson (Commercial agreements), Gulestan Ali (Compliance), Nicklas Thorgerzon (IT/GDPR), Jonatan Stentorp (Employment) and Sofia Haggren (Financing).

Related

Vinge advises Platzer on a combined asset swap transaction with the Port of Gothenburg concerning properties in Arendal

 Vinge has advised Platzer on a combined asset swap transaction with the Port of Gothenburg comprising the sale of the property Arendal 1:28, parts of the properties Arendal 1:29 and Arendal 1:31, and the acquisition of part of the property Arendal 764:291.
April 08, 2026

Vinge has advised SEB, Swedbank and Danske Bank in connection with a bridge facility to Catena

 Vinge has advised Skandinaviska Enskilda Banken AB (publ), Swedbank AB (publ) and Danske Bank A/S in their capacities as mandated lead arrangers and bookrunners in connection with a term loan bridge facility in an aggregate amount of SEK 4,360,000,000, EUR 195,000,000 and DKK 170,000,000 to Catena AB (publ).
April 02, 2026

Vinge advises the founders of Nordic Knots in connection with the investment in the company by Imaginary Ventures and other investors

Vinge has advised the founders of Nordic Knots in connection with an investment in the company led by Imaginary Ventures, with additional investors including Creades, IRIS Ventures and St Dominique Capital.
April 02, 2026